{"disease":{"id":"refractory-solid-tumors","name":"refractory solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06030869","title":"MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT03886831","title":"A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT04718675","title":"A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":135,"lead_sponsor_name":"Kronos Bio","has_results":false},{"nct_id":"NCT04447755","title":"A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05320640","title":"Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03863145","title":"Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Cosmo Technologies Ltd","has_results":false},{"nct_id":"NCT03245151","title":"Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT05608148","title":"Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":61,"lead_sponsor_name":"Kyushu University","has_results":false},{"nct_id":"NCT03052205","title":"A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Idera Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05811975","title":"KSX01-TCRT Injection Project in Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"TCRx Therapeutics Co.Ltd","has_results":false},{"nct_id":"NCT02482441","title":"A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"OncoMed Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05539833","title":"KSH01-TCRT Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"TCRx Therapeutics Co.Ltd","has_results":false},{"nct_id":"NCT06006273","title":"A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03810742","title":"Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"PharmaEngine","has_results":false},{"nct_id":"NCT01282697","title":"Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT07509034","title":"Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03245450","title":"Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT07327411","title":"Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Second Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT02383368","title":"A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07444918","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03458728","title":"Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT04685473","title":"Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Taivex Therapeutics Corporation","has_results":false},{"nct_id":"NCT03451825","title":"Phase I/II Study of Avelumab in Pediatric Cancer Participants","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT03195764","title":"Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Taivex Therapeutics Corporation","has_results":false},{"nct_id":"NCT04869475","title":"Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04200404","title":"A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"CStone Pharmaceuticals","has_results":false},{"nct_id":"NCT00321581","title":"AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04686383","title":"Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Calgent Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT05187858","title":"A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Lupin Ltd.","has_results":false},{"nct_id":"NCT06494579","title":"Lamivudine for Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Thomas Marron","has_results":false},{"nct_id":"NCT06150365","title":"Personalized KSX01-TCRT in Patients With Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04324372","title":"Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT03096340","title":"Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Intezyne Technologies, Inc.","has_results":false},{"nct_id":"NCT03247309","title":"TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Immatics US, Inc.","has_results":false},{"nct_id":"NCT07040943","title":"Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT07100210","title":"A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Xingchen Peng","has_results":false},{"nct_id":"NCT02688881","title":"Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT02512926","title":"Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT02963610","title":"Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":true},{"nct_id":"NCT03349073","title":"An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Taivex Therapeutics Corporation","has_results":false},{"nct_id":"NCT02691793","title":"Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT02450123","title":"Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05531708","title":"Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shanghai Pudong Hospital","has_results":false},{"nct_id":"NCT05655598","title":"TAS-116 Plus Palbociclib in Breast and Rb-null Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Brown University","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}